Introduction
============

The metabolic syndrome is characterized by abdominal adiposity, dyslipidemia, elevated glucose and blood pressure.^[@bib1]^ The metabolic syndrome is strongly linked to cardiovascular events,^[@bib2]^ cancer^[@bib3]^ and mortality.^[@bib4]^ Given that the metabolic syndrome is becoming a worldwide pandemic, with prevalence rates between 20 and 30% among the adult population,^[@bib5]^ the identification of modifiable risk factors associated with the development of metabolic syndrome is important to public health.

Sleep is a basic human need; it takes up more time in a day than any other activity. Too short or too long a duration of habitual sleep are currently thought to be important lifestyle risk factors for such metabolic diseases such as diabetes,^[@bib6],\ [@bib7],\ [@bib8]^ obesity^[@bib8],\ [@bib9],\ [@bib10]^ and cardiovascular disease, (and hypertension in particular^[@bib11],\ [@bib12]^) and sleep duration may also be a significant predictor of all-cause mortality in prospective population studies.^[@bib13],\ [@bib14]^

Several epidemiological studies have been conducted to investigate the association between length of sleep and metabolic syndrome, with inconsistent results. A number of studies in adults have demonstrated an association between short sleep duration and metabolic syndrome.^[@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21]^ Conversely, some of these studies also showed that long sleep duration was associated with metabolic syndrome.^[@bib22],\ [@bib23]^ To our knowledge, there has been no published systematic literature review that has characterized the magnitude of these associations. Therefore, we have summarized published data from cross-sectional and prospective cohort studies, and performed a meta-analysis to obtain a quantitative estimate of the risk.

Materials and methods
=====================

We planned, conducted and reported this systematic review according to widely accepted standards of quality for reporting meta-analyses of observational studies in epidemiology ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).^[@bib24]^

Literature search
-----------------

A master\'s level medical librarian with experience in systematic reviews participated in designing the search strategy. We searched PubMed, Cochrane CENTRAL, PsycINFO and EMBASE via Elsevier from the date of inception until 26 November 2012. A PubMed search for studies on sleep and metabolic syndrome was conducted without restrictions by combining synonymous or related search terms for sleep and metabolic syndrome. The keywords used in the PubMed search were converted to search tags for Cochrane CENTRAL, PsycINFO and EMBASE ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In addition, manual searches of the bibliographies of the relevant articles were performed to identify additional studies.

Study selection
---------------

Several criteria were used to identify relevant studies for the meta-analysis. The studies included had an observational design, including cross-sectional studies and cohort studies, and were conducted in human adults. The exposure of interest was sleep duration. The outcome of interest was metabolic syndrome. Finally, the adjusted relative risk estimates (odds ratios \[OR\] in cross-sectional studies) and their corresponding 95% confidence intervals (CI), or sufficient data to calculate these values, were reported. We selected full-length articles without language restriction. Disagreements between the reviewers were resolved by consensus. We also checked the reference lists of included publications using a cross-reference table.

Data extraction
---------------

Two reviewers (J-SY and C-WS) independently extracted the data from original reports. The adjusted risk estimates that reflected the most comprehensive control were extracted to avoid potential confounding variables. The following predictors of sleep duration were extracted: study characteristics (study name, authors, publication year, country of data collection, number of participants and follow-up years for cohort studies), participants\' characteristics (age range or mean age and sex) and metabolic syndrome measures. The methodological quality of the eligible non-randomized studies reviewed in meta-analyses was assessed according to the seven domains proposed as being fundamental to the methodological quality of the included studies ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}).^[@bib25],\ [@bib26]^

Statistical analysis
--------------------

We used adjusted relative risk or OR with the corresponding 95% CI for the meta-analysis. If OR estimates for an outcome were reported in a study, we selected the OR that was adjusted for most covariates and that was derived by using data from the most subjects in the study. Pooled OR estimates were obtained using a random-effect model. For consistency, we chose the group that slept 7 h per day as the reference category. When the reference category differed in each study, we used variances in the independent observations to obtain the CI of OR for each sleep category. When the variables X and Y were considered, the variance was as follows: or, in another formula: . This correlation coefficient could only be assessed within the studies in which all individual data were presented. By comparing the variance with the reference sleep duration category, we estimated the pooled risk and 95% CI of metabolic syndrome for the short- and long-sleep categories separately. For the meta-analysis, the statistical heterogeneity between the studies was assessed using Q statistics.^[@bib27]^ For the Q statistics, heterogeneity was considered to be present if *P*\<0.1. We defined low, moderate and high heterogeneity as *I*^2^ values of 25, 50 and 75%, respectively. Publication bias was evaluated using Egger\'s test and Begg\'s test. In the presence of publication bias, the *P*-values for Egger\'s test and Begg\'s test are less than 0.05. Subgroup meta-analyses were conducted according to the study design (cross-sectional study or cohort study), the different methods used to measure sleep duration, the definition of metabolic syndrome used and the subject\'s gender, age and geographic region. We also performed a two-stage random-effects dose-risk meta-analysis to examine a nonlinear dose--response relationship between length of sleep and metabolic syndrome. After modeling the length of sleep using restricted cubic splines with three knots at fixed percentiles (10, 50 and 90%) of the distribution,^[@bib28],\ [@bib29],\ [@bib30]^ we used a generalized least-squares method^[@bib31]^ and a multivariate maximum likelihood method to estimate a summary of nonlinear dose-risk relationship, taking into account random effects.^[@bib32]^ All statistical analyses were performed using Stata software Version 12.0 (Stata Corp, College Station, TX, USA).

Results
=======

Literature searches and study selection
---------------------------------------

[Figure 1](#fig1){ref-type="fig"} shows a flow diagram of the procedure used to identify the relevant studies. Briefly, we identified 36 potentially relevant articles on sleep duration in relation to metabolic syndrome after an initial screening of titles and abstracts. After we examined the 36 assembled articles, 24 articles were excluded ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). Finally, we identified 12 articles including 15 studies that investigated the association between sleep duration and metabolic syndrome risk; 3 articles reported separate results for stratification by gender.^[@bib15],\ [@bib20],\ [@bib23]^ No additional studies were identified via cross-referencing.

Study characteristics
---------------------

Most of studies used multivariate logistic regression to adjust for potential confounders. The 12 cross-sectional^[@bib17],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22],\ [@bib23],\ [@bib33],\ [@bib34],\ [@bib35],\ [@bib36]^ studies, with 76 027 participants, including 14 404 metabolic syndrome patients and the three cohort^[@bib15],\ [@bib18]^ studies, with 2055 participants, are represented in [Table 1](#tbl1){ref-type="table"}. A total of 283 metabolic syndrome cases occurred during follow-up in the three cohort studies. Three studies^[@bib23],\ [@bib34],\ [@bib35]^ defined metabolic syndrome using the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP-III).^[@bib1]^ Four studies^[@bib15],\ [@bib20],\ [@bib22],\ [@bib33]^ assessed metabolic syndrome using the modified NCEP ATP-III. Two studies^[@bib19],\ [@bib36]^ used the American Heart Association/National Heart Lung and Blood Institute\'s (AHA/NHLBI) criteria.^[@bib37]^ One study^[@bib21]^ used the modified criteria of the AHA/NHLBI and assessed abdominal obesity according to the World Health Organization\'s definition. Two studies^[@bib17],\ [@bib18]^ used the Japanese criteria for metabolic syndrome. Eight studies^[@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib23],\ [@bib33],\ [@bib34]^ assessed sleep duration using a questionnaire and four studies^[@bib15],\ [@bib22],\ [@bib35],\ [@bib36]^ used an interview. Of the included studies, five were conducted in men,^[@bib15],\ [@bib18],\ [@bib20],\ [@bib23],\ [@bib35]^ four in women^[@bib15],\ [@bib20],\ [@bib23],\ [@bib35]^ and eight in both genders;^[@bib17],\ [@bib19],\ [@bib21],\ [@bib22],\ [@bib33],\ [@bib34],\ [@bib35],\ [@bib36]^ seven were conducted in Asia,^[@bib15],\ [@bib17],\ [@bib18],\ [@bib20],\ [@bib22],\ [@bib33],\ [@bib35]^ four in the United States^[@bib19],\ [@bib21],\ [@bib34],\ [@bib36]^ and one in Europe.^[@bib23]^ All of the studies were published in the 2000s. The study periods ranged from 1 to 7 years. The patients\' age ranged from ⩾18 to ⩾50 years. The study quality was high in 10 of the 15 included studies (3 cohort and 12 cross-sectional studies).

Short duration of sleep
-----------------------

Short duration of sleep was significantly associated with a greater risk of developing metabolic syndrome in four of the twelve cross-sectional studies and two of the three cohort studies. The pooled OR between short sleep and metabolic syndrome was 1.27 (95% CI=1.10--1.48, *I*^2^=75.5%) in the 12 cross-sectional studies and 1.62 (95% CI=0.74--3.55, *I*^2^=71.4%) in the 3 cohort studies ([Figure 2](#fig2){ref-type="fig"}). Significant heterogeneity was observed (*P*\<0.1). No publication bias was detected with Egger\'s test (*P*=0.17) or Begg\'s test (*P*=0.92) ([Figure 3](#fig3){ref-type="fig"}).

Subgroup analyses of the cross-sectional studies are shown in [Table 2](#tbl2){ref-type="table"}. There were significant differences in the mean age, cohort-based group, definition of metabolic syndrome, quality of study and sleeping measure (*P* for heterogeneity \<0.1). No significant group difference was found for gender or location.

Long duration of sleep
----------------------

Long duration of sleep was associated with a greater risk of developing metabolic syndrome in five of the eleven cross-sectional studies and none of the two cohort studies. The pooled OR between long sleep and metabolic syndrome was 1.23 (95% CI=1.02--1.49, *I*^2^=75.8%) in the 11 cross-sectional studies and 1.62 (95% CI=0.86--3.04, *I*^2^=0.0%) in the 2 cohort studies. Significant heterogeneity was observed between the 11 cross-sectional studies (*P*\<0.1). No publication bias was detected with Egger\'s test (*P*=1.33) or Begg\'s test (*P*=0.95) ([Figure 3](#fig3){ref-type="fig"}).

Subgroup analyses of the cross-sectional studies are shown in [Table 2](#tbl2){ref-type="table"}. There were significant differences in location, definition of metabolic syndrome, quality of study and sleeping measure (*P* for heterogeneity \<0.1). No significant group difference was found for gender, age or cohort-based group.

Dose--response relationship
---------------------------

When we assessed the dose--response relationship between sleep duration and metabolic syndrome, we found some evidence of a statistically significant departure from linearity (*P*\<0.001; [Figure 4](#fig4){ref-type="fig"}). Among the shorter and longer sleepers, the risk of metabolic syndrome might increase gradually compared with individuals who report sleeping 7 h per day. Compared with the reference level, the combined odds ratios of metabolic syndrome were 1.33 (95% CI=1.07--1.65) for ⩽5 h per day, 1.21 (95% CI=1.04--1.41) for 5.5 h per day, 1.11 (95% CI=1.02--1.21) for 6 h per day, 1.04 (95% CI=1.00--1.07) for 6.5 h per day, 1.07 (95% CI=1.00--1.13) for 8 h per day, 1.15 (95% CI=1.03--1.28) for 8.5 h per day, 1.26 (95% CI=1.07--1.49) for 9 h per day and 1.38 (95% CI=1.10--1.74) for ⩾9.5 h per day in the eight cross-sectional studies.^[@bib17],\ [@bib19],\ [@bib22],\ [@bib23],\ [@bib33],\ [@bib35],\ [@bib36]^ There was significant between-study heterogeneity among study-specific trends defined by the coefficient of the first and second spline transformations of sleep duration (*P*\<0.1).

Sensitivity analyses in the cross-sectional studies
---------------------------------------------------

We included five studies of healthy populations and participants not taking antihypertensive medication for our sensitivity analyses.^[@bib17],\ [@bib20],\ [@bib22],\ [@bib36]^ The sensitivity meta-analyses yield somewhat weakened summary ORs of 1.22 (95% CI=0.96--1.54) for short sleep durations and 1.14 (95% CI=0.98--1.32) for long sleep durations. There was heterogeneity for short sleep (*I*^2^=33%, *P*=0.20) and long sleep (*I*^2^=84.6%, *P*\<0.1). We also excluded two studies from our sensitivity analyses, as they reported the association between sleep duration and metabolic syndrome in police officers. The sensitivity meta-analyses yielded nearly identical summary ORs of 1.25 (95% CI=1.07--1.46; *I*^2^=78.6%) for short sleep and 1.22 (95% CI=1.22--1.48; *I*^2^=77.9%) for long sleep.

Discussion
==========

To our knowledge, this is the first quantitative systematic review of observational studies investigating the effect of sleep duration on the risk of metabolic syndrome using data from cross-sectional and cohort studies. This study shows a significant increased risk of metabolic syndrome on either end of the distribution of sleep duration in the cross-sectional studies, but not in the cohort studies. Pooled analyses of cross-sectional studies indicate that short sleepers have a greater risk of metabolic syndrome compared with those who sleep 7--8 h per night. Longer sleepers also show an increased risk for metabolic syndrome, confirming the presence of a U-shaped association in the cross-sectional studies. There was some heterogeneity between studies, no publication bias and no differences between men and women. Furthermore, compared with the 7-h sleep duration, U-shaped associations between sleep duration and the risk of metabolic syndrome were observed in a dose--response meta-analysis of eight cross-sectional studies. This complementary investigation may strengthen the plausibility of a causal association, and allow us to draw an overview of the nonlinear relationship between sleep duration and metabolic syndrome risk.

Causal mechanisms relating the short duration of sleep to adverse health outcomes include changes in circulating levels of leptin and ghrelin, which in turn would increase appetite and calorie intake, reduce energy expenditure and impair glycemic control.^[@bib38],\ [@bib39]^ Increased cortisol secretion and altered growth hormone metabolism have also been implicated.^[@bib40]^ Low-grade inflammation is also activated during short sleep.^[@bib41]^ Conversely, the association between a long duration of sleep and metabolic syndrome may be explained by residual confounding factors and comorbidity. Unrecognized confounders such as sleep fragmentation, fatigue and depression^[@bib42]^ could lead to both metabolic syndrome and an increased need for sleep.^[@bib43]^ Long sleepers have less waking time to undertake physical activity, which may contribute to this association.^[@bib44]^ Lifestyle interventions that aim to reduce weight and physical activity may ameliorate the risk of diabetes in long sleepers.^[@bib45]^ Furthermore, obesity itself is regarded as a chronic inflammatory condition. The elevated levels of proinflammatory cytokines have been considered as factors that contribute to increased sleep durations,^[@bib46]^ which promotes insulin resistance.

There are several possible reasons for the risk of metabolic syndrome according to sleep duration. Hypothalamic--pituitary--adrenal hyperactivity has a role in the pathogenesis of the metabolic syndrome,^[@bib47]^ and activation of the hypothalamic--pituitary--adrenal axis can lead to sleeplessness.^[@bib14]^ Sleep fragmentation or restriction leads to insulin resistance,^[@bib48]^ which appears to have a key role in the pathophysiology of metabolic syndrome.^[@bib49]^ In addition, longer sleep could be associated with circadian and hormonal alternations.^[@bib50]^ A previous report suggested that the nocturnal intervals of high plasma melatonin levels, increasing cortisol levels, low body temperature and increasing sleepiness are longer in long sleepers (\>9 h) than short sleepers (\<6 h).^[@bib51]^ However, the mechanisms that underline these associations are not fully understood. An investigation reporting an association between variants of the human *CLOCK* gene and sleep duration may prove fruitful in this regard.^[@bib52]^ Some evidence has suggested that the covariation among sleep parameters and clusters of metabolic syndrome may be partially related to genetic influences. For example, disruptions of the core *CLOCK* genes that regulate endogenous circadian rhythmicity are linked to perturbations in glucose metabolism, adipocyte and vascular function,^[@bib53]^ obesity and metabolic syndrome.^[@bib54]^ Thus, it is possible that short and long sleep are linked to metabolic syndrome risk through different pathways.

There were significant differences in the relationship between sleep duration and metabolic syndrome in different groups based on age, location, type of cross-sectional study (community based or hospital based), sleep measure, quality of study and definition of metabolic syndrome. However, due to the limited number of studies within several groups, these results should be interpreted cautiously. For short duration of sleep, a significant 33% increase in metabolic syndrome was observed in hospital-based studies. Not surprisingly, hospital-based samples of patients suffering from disease are at a higher risk of developing metabolic syndrome, as metabolic syndrome itself is a cluster of risk factors of metabolic abnormalities, and short sleep duration is a risk behavior for the development of chronic disease, particularly stroke and cancer,^[@bib55]^ which can strengthen the relationship between short sleep and metabolic syndrome.

We found that the association was stronger for both long and short sleep in cross-sectional studies that identified habitual sleep duration using questionnaires rather than interviews. One possible explanation is that the cross-sectional studies could contain sources of bias, such as recall bias. Therefore, overestimation or underestimation of sleep duration per night may be caused by a single self-reported survey item that may not capture the subject\'s actual amount of sleep per night. For short sleep, there was a significant association with middle age. This finding may be explained by the distribution of weekly averaged sleep duration. Sleep duration decreases steadily in both genders from the end of adolescence to the age of menopause. From that age on, sleep duration increases slightly with age.^[@bib52]^ This distribution would implicitly allow the inclusion of many people with short sleep. Thus, the inclusion of only middle-aged people may have led to the stronger estimates.

Although our meta-analysis included only multivariable adjusted ORs, there is evidence of heterogeneity across the studies in both study designs. This heterogeneity may be attributable to differences in study design, sample size, analytic strategies, participant characteristics, the diagnostic criteria for metabolic syndrome, study quality and the measurement of sleep duration. To account for this heterogeneity, we used random-effects models of the meta-analyses, and conducted subgroup analyses using fixed-effects models; however, the results were not significantly changed.

This meta-analysis has several strengths and limitations. The primary strength is that this is the first meta-analysis that examines the relationship between sleep duration and metabolic syndrome based on a comprehensive literature search. In addition, a dose--response meta-analysis using restricted cubic splines revealed a U-shaped relationship between sleep duration and the risk of metabolic syndrome, despite the heterogeneous categorization of sleep duration in the individual studies. A limitation of this approach is that it depends on means, median or midpoints of the sleep-duration categories. The estimates of risk in this approach are therefore slightly less accurate than in the individual patient data meta-analyses. We found no publication bias in any of the analyses. Despite the calculation of risk estimates that reflected the greatest degrees of controlling for potential confounders, some limitations must be considered when interpreting the meta-analyses results. As it is impossible to completely adjust for general health status, residual confounders must always be considered while interpreting results from observational studies. Finally, a major limitation was the evidence of heterogeneity across the studies, especially that resulting from heterogeneous sleep-measure methods, quality of study and variations in the definition of metabolic syndrome. Thus, the results of this analysis should be interpreted cautiously.

In this systemic review and meta-analysis of epidemiological studies of the association between sleep duration and metabolic syndrome, both short sleepers and long sleepers are at risk of metabolic syndrome in cross-sectional studies, but not in cohort studies; this is consistent with the results from an analysis using nonlinear dose--response method in the cross-sectional studies. Therefore, short and long sleep durations are risky behaviors for increasing the risk of metabolic syndrome and thus have important public health implications, as sleep habits are amenable to behavioral interventions. However, the available data are sparse, and further studies, especially longitudinal studies, are needed to enable more in-depth analyses, more precise and stable estimates of the association and a better understanding of the potential role of sleep duration in metabolic syndrome risk. Further studies could also shed light on possible sources of heterogeneity across the studies included in this meta-analysis.
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![Flow diagram for search strategy and study selection process.](nutd20138f1){#fig1}

![Forest plots of the risk of metabolic syndrome associated with (**a**) short duration of sleep compared with the reference group, and (**b**) long duration of sleep compared with the reference group. The results are expressed as odds ratio (relative risk in cohort studies) and 95% confidence intervals.](nutd20138f2){#fig2}

![Inverse funnel plot with 95% CIs of the odds ratio of metabolic syndrome according to (**a**) short duration of sleep compared with the reference group (Egger\'s test, *P*=0.17; Begg\'s test, *P*=0.92), and (**b**) long duration of sleep compared with the reference group (Egger\'s test, *P*=1.33; Begg\'s test, *P*=0.95).](nutd20138f3){#fig3}

![The odds ratio (filled circle) with 95% CI (solid longitudinal line) for the dose--response relationship between sleep duration and the risk of metabolic syndrome in the cross-sectional studies. The reference duration of 7 h per day was used to estimate all odds ratios. The eight cross-sectional studies (out of 12) with at least four levels of sleep categories were used in a restricted cubic spline random-effects meta-analysis.](nutd20138f4){#fig4}

###### Characteristics of cross-sectional and cohort studies included in the meta-analysis

  *Author study name*                       *Country observation period*   *No. of participants*  *No. of cases*    *Age range mean (s.d.)*            *Gender population*             *Metabolic syndrome assessment*   *Sleeping assessment*      *Sleep (h)*     *Odds ratio (95% CI)*    *Adjusted covariates*
  ---------------------------------------- ------------------------------ ----------------------- ---------------- ------------------------- ---------------------------------------- --------------------------------- ----------------------- ------------------- ----------------------- -----------------------
  *Cross-sectional studies*                                                                                                                                                                                                                                                                 
   Santos *et al.*^[@bib23]^                    Portugal 1999--2003                 832           96                        18--92                             Men                              NCEP ATP-III                 Questionnaire              ⩽6          1.40 (0.76--2.60)             1, 3, 4, 5
                                                                                                  216                                                                                                                                                    7          1.00 (Reference)                    
                                                                                                  214                                                                                                                                                    8          1.10 (0.73--1.70)                   
                                                                                                  227                                                                                                                                                   ⩾9          1.50 (0.90--2.60)                   
                                                                                   1332           153                                                         Women                                                                                     ⩽6          0.92 (0.55--1.50)                   
                                                                                                  270                                                                                                                                                    7          1.00 (Reference)                    
                                                                                                  401                                                                                                                                                    8          1.20 (0.80--1.70)                   
                                                                                                  388                                                                                                                                                   ⩾9          2.00 (1.30--3.00)                   
   Choi *et al.*^[@bib33]^ KNHNS, 2001               Korea 2001                     633           217                     44.1 (0.4)                           Both                         Modified NCEP ATP-III            Questionnaire              ⩽5          1.20 (0.87--1.60)        1, 2, 3, 4, 5, 6, 12
                                                                                   1056           293                                                                                                                                                    6          1.10 (0.85--1.30)                   
                                                                                   1182           274                                                                                                                                                    7          1.00 (Reference)                    
                                                                                   1056           293                                                                                                                                                    8          1.30 (1.00--1.70)                   
                                                                                    296           94                                                                                                                                                    ⩾9          1.70 (1.20--2.50)                   
   Hall *et al.*^[@bib36]^ AHAB                         USA                         187           58                        30--54                             Both                               AHA/NHLBI                    Interview                \<6         1.80 (1.20--2.80)        1, 2, 4, 8, 9, 10, 14
                                                                                    402           101                                                                                                                                                 6--6.99       1.50 (1.10--2.10)                   
                                                                                    525           100                                                                                                                                                  7--8         1.00 (Reference)                    
                                                                                    100           25                                                                                                                                                    \>8         1.80 (1.00--3.10)                   
                                                                                                                                              Not taking antihypertensive medication                                              \<6            1.80 (1.10--2.70)                          
                                                                                                                                                                                                                                                      6--6.99       1.50 (1.00--2.10)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                        \>8         1.60 (0.91--3.00)                   
   Arora *et al.*^[@bib22]^ GBCS                       China                       1142           329                       50--96                             Both                         Modified NCEP ATP-III              Interview                \<6         0.97 (0.88--1.10)        1, 2, 3, 4, 5, 8, 11
                                                                                   2020           570                                                                                                                                                  6--7         1.00 (0.93--1.10)                   
                                                                                   2303           603                                                                                                                                                  7--8         1.00 (Reference)                    
                                                                                   1995           575                                                                                                                                                  8--9         1.20 (1.10--1.30)                   
                                                                                    762           226                                                                                                                                                   ⩾9          1.20 (1.10--1.30)                   
                                                                                                                                                             Healthy                                                                                    \<6         0.93 (0.84--1.00)                   
                                                                                                                                                                                                                                                       6--7         0.98 (0.90--1.10)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                       8--9         1.10 (1.10--1.20)                   
                                                                                                                                                                                                                                                        ⩾9          1.20 (1.10--1.30)                   
                                                                                                                            51--61                          Middle age                                                                                  \<6         1.10 (0.91--1.20)                   
                                                                                                                                                                                                                                                       6--7         1.00 (0.92--1.10)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                       8--9         1.10 (1.00--1.30)                   
                                                                                                                                                                                                                                                        ⩾9          1.30 (1.20--1.50)                   
                                                                                                                             \>61                            Old age                                                                                   \< 6         0.93 (0.83--1.10)                   
                                                                                                                                                                                                                                                       6--7         0.98 (0.89--1.10)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                       8--9         1.20 (1.10--1.30)                   
                                                                                                                                                                                                                                                        ⩾9          1.10 (0.95--1.30)                   
   Kobayashi *et al.*^[@bib17]^                      Japan 2008                    7295           641                     44.8 (12.8)                          Both                                 JASSO                    Questionnaire              \<6         1.40 (1.20--1.60)           1, 2, 4, 6, 13
                                                                                   11355          905                                                                                                                                                 6--6.99       1.10 (0.95--1.30)                   
                                                                                   6732           592                                                                                                                                                 7--7.99       1.00 (Reference)                    
                                                                                   2410           233                                                                                                                                                   ⩾8          0.98 (0.83--1.20)                   
   Najafian *et al.*^[@bib35]^ IHHP               Iran 1999--2006                  1447           485                    38.89 (14.93)                         Both                             NCEP ATP-III                   Interview                ⩽5          1.50 (1.30--1.70)                1, 2
                                                                                   2336           575                                                                                                                                                    6          1.20 (1.10--1.40)                   
                                                                                   7622           1654                                                                                                                                                 7--8         1.00 (Reference)                    
                                                                                   1089           223                                                                                                                                                   ⩾9          0.79 (0.68--0.94)                   
                                                                                   5976                                                                        Men                                                                                      ⩽5          1.30 (0.99--1.60)                  1
                                                                                                                                                                                                                                                         6          1.10 (0.89--1.30)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                        ⩾9          0.77 (0.55--1.10)                   
                                                                                   6320                                                                       Women                                                                                     ⩽5          1.70 (1.40--2.00)                   
                                                                                                                                                                                                                                                         6          1.30 (1.10--1.50)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                        ⩾9          0.81 (0.67--0.98)                   
                                                                                   10699                                     \<60                              Both                                                                                     ⩽5          1.70 (1.50--2.00)                  2
                                                                                                                                                                                                                                                         6          1.20 (1.10--1.40)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                        ⩾9          0.84 (0.70--1.00)                   
                                                                                   1597                                      \>60                              Both                                                                                     ⩽5          1.10 (0.84--1.40)                   
                                                                                                                                                                                                                                                         6          1.10 (0.79--1.40)                   
                                                                                                                                                                                                                                                       7--8         1.00 (Reference)                    
                                                                                                                                                                                                                                                        ⩾9          0.61 (0.40--0.92)                   
   Sabanayagam *et al.*^[@bib19]^ NHANES           USA 2005--2008                   935           377                    44.63 (0.46)                          Both                               AHA-NHLBI                  Questionnaire              ⩽5          1.20 (0.98--1.60)        1, 2, 3, 4, 5, 8, 10
                                                                                   1412           548                                                                                                                                                    6          1.10 (0.93--1.30)                   
                                                                                   1777           650                                                                                                                                                    7          1.00 (Reference)                    
                                                                                   1621           579                                                                                                                                                    8          0.92 (0.76--1.10)                   
                                                                                    377           135                                                                                                                                                   ⩾9          0.97 (0.69--1.40)                   
   McCanlies *et al.*^[@bib34]^                         USA                         28            7                          39.61                             Both                             NCEP ATP-III                 Questionnaire             \< 6         2.30 (0.81--6.50)             1, 2, 3, 4
                                                                                    70            7                                                           Police                                                                                    ⩾6          1.00 (Reference)                    
   Wu *et al.*^[@bib20]^                               Taiwan                       954           198                     47.1 (12.0)                          Men                          Modified NCEP ATP-III            Questionnaire              \<6         1.30 (1.00--1.60)            1, 3, 4, 5, 7
                                                     2006--2009                    3202           535                     44.8 (11.1)                                                                                                                  6--8         1.00 (Reference)                    
                                                                                    142           27                      52.3 (12.2)                                                                                                                  \> 8         1.40 (0.82--2.50)                   
                                                                                    794           94                                                          Women                                                                                    \< 6         1.00 (0.72--1.50)                   
                                                                                   1909           172                                                                                                                                                  6--8         1.00 (Reference)                    
                                                                                    99            9                                                                                                                                                    \> 8         0.90 (0.32--2.50)                   
   Yoo *et al.*^[@bib21]^                               USA                         32            10                        22--60                             Both                          Modified AHA-NHLBI              Questionnaire              ⩽6          2.30 (0.71--7.50)           1, 2, 4, 8, 17
                                                                                    53            13                                                          Police                                                                                 \>6--\<8       1.00 (Reference)                    
                                                                                    21            12                                                                                                                                                    ⩾8          1.90 (1.30--18.0)                   
                                                                                                                                                                                                                                                                                            
  *Cohort studies*                                                                                                                                                                                                                                                                          
   Choi *et al.*^[@bib15]^ KGRC                   Korea 2005--2009                  27            5                         40--70                             Men                          Modified NCEP ATP-III              Interview               \< 6         0.62 (0.24--1.60)            1, 4, 5, 7, 8
                                                                                    209           49                                                                                                                                                  6--7.9        1.00 (Reference)                    
                                                                                    132           23                                                                                                                                                  8--8.9        0.74 (0.44--1.20)                   
                                                                                    18            5                                                                                                                                                     ≥10         1.60 (0.61--4.00)                   
                                                                                    68            20                                                          Women                                                                                     \<6         1.80 (1.10--3.00)          1, 4, 5, 7, 8, 15
                                                                                    403           61                                                                                                                                                  6--7.9        1.00 (Reference)                    
                                                                                    226           34                                                                                                                                                  8--8.9        0.91 (0.59--1.40)                   
                                                                                    24            7                                                                                                                                                     ⩾10         1.70 (0.71--3.90)                   
   Otsuka *et al.*^[@bib18]^                      Japan 2005--2009                  120           20                        35--63                             Men                          The Japanese criteria            Questionnaire              ⩽5          3.20 (1.50--6.60)           1, 4, 5, 6, 16
                                                                                    559           46                                                                                                                                                   5--6         1.80 (0.96--3.50)                   
                                                                                    269           13                                                                                                                                                    \>6         1.00 (Reference)                    

Abbrevations: AHA-NHLBI, American Heart Association/National Heart Lung and Blood Institute; AHAB, Adult Health and Behavior; CES-D, Center for Epidemiological Studies Depression Scale; CI, confidence interval; GBCS, The Guangzhou Biobank Cohort Study; IHHP, Isfahan Healthy Heart Program; JASSO, Japan Society for the Study of Obesity; KGRC, The Korean Genomic Rural Cohort; KNHNS, Korean National Health and Nutrition Survey; NCEP ATP-III, National Cholesterol Education Adult Treatment Panel III; PSQI, Pittsburgh Sleep Quality Index; PSS, Perceived Stress Scale; 1, age; 2, sex; 3, education; 4, smoke; 5, alcohol; 6, exercise; 7, body mass index; 8, physical activity; 9, race; 10, depression; 11, diagnosed mental illness, insomnia, use of hypnotics, daytime sleepiness, snoring, mean systolic pressure, glucose, total cholesterol and triglycerides; 12, family history of hypertension or diabetes, residential area and monthly income; 13, myocardial infarction and cerebral infarction; 14, low-density lipoprotein cholesterol; 15, menopause; 16, frequency of vegetable intake, frequency of oily food intake and frequency of salty food intake; 17, burnout, Center for Epidemiological Studies Depression Scale and Perceived Stress Scale.

###### Subgroup meta-analyses of cross-sectional studies to explore sources of heterogeneity

  *Subgroups*                            *Short sleep*     *Long sleep*         
  ------------------------------------- --------------- ------------------- --- -------------------
  *Gender*                                                                      
   Men                                         3         1.27 (1.08, 1.49)   3   1.03 (0.80, 1.33)
   Women                                       3         1.49 (1.29, 1.72)   3   0.94 (0.80, 1.12)
                                                             *P*=0.156               *P*=0.588
                                                                                
  *Mean age (years)*                                                            
   [a](#t2-fn2){ref-type="fn"}Middle           5         1.34 (1.21, 1.48)   4   1.15 (1.04, 1.28)
   [b](#t2-fn3){ref-type="fn"}Elderly          2         0.96 (0.86, 1.06)   2   1.03 (0.90, 1.18)
                                                             *P*\<0.1                *P*=0.210
                                                                                
  *Location*                                                                    
   Asia                                        6         1.18 (1.11, 1.26)   6   1.08 (1.01, 1.16)
   Europe                                      2         1.09 (0.74, 1.61)   2   1.81 (1.30, 2.52)
   USA                                         4         1.40 (1.15, 1.72)   3   1.18 (0.89, 1.56)
                                                             *P*=0.237               *P*\<0.1
                                                                                
  *Cohorts-based*                                                               
   Community                                   6         1.15 (1.07, 1.23)   6   1.12 (1.03, 1.21)
   Hospital                                    3         1.33 (1.18, 1.49)   3   1.01 (0.86, 1.18)
                                                             *P*\<0.1                *P*=0.263
                                                                                
  *Measure of sleeping*                                                         
   Interview                                   3         1.14 (1.06, 1.23)   3   1.09 (1.00, 1.19)
   Questionnaire                               9         1.29 (1.18, 1.42)   8   1.16 (1.03, 1.31)
                                                             *P*\<0.1                *P*\<0.1
                                                                                
  *Metabolic syndrome*                                                          
   NCEP ATP-III                                4         1.48 (1.30, 1.68)   4   0.93 (0.80, 1.07)
   Modified NCEP ATP-III                       4         1.02 (0.94, 1.11)   4   1.24 (1.13, 1.36)
   AHA-NHLBI                                   2         1.36 (1.10, 1.67)   2   1.15 (0.86, 1.54)
   Modified AHA-NHLBI                          1         2.30 (0.71, 7.50)   1   1.89 (0.51, 7.00)
   JASSO                                       1         1.39 (1.21, 1.60)   1   0.98 (0.83, 1.16)
                                                             *P*\<0.1                *P*\<0.1
                                                                                
  *Quality of study*                                                            
   High                                        7         1.06 (0.99, 1.15)   6   1.23 (1.13, 1.34)
   Low                                         5         1.44 (1.31, 1.58)   5   0.96 (0.86, 1.07)
                                                             *P*\<0.1                *P*\<0.1

Abbrevations: AHA-NHLBI, American Heart Association/National Heart Lung and Blood Institute; CI, confidence interval; JASSO, Japan Society for the Study of Obesity; NCEP ATP-III, National Cholesterol Education Adult Treatment Panel III; OR, odds ratios.

Middle, \<60 or ⩽61.

Elderly, \>60 or ⩾61.
